NCT04863703Active, not recruiting
Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
Source: ClinicalTrials.gov · Last updated 15 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Portal hypertension (PH) is one of the key drivers of clinical deteoration in patients with liver cirrhosis. It has been demonstrated that antiviral therapy in patients with chronic hepatitis C infection leads to a decrease of PH and is associated with an improved outcome. Recently, Bulevirtide was approved for the treatment of patients coinfected with hepatitis B (HBV) and chronic hepatitis delta (HDV) infection, which helps to achieve viral supression in these patients. This study investigates the potential effects of viral supression on PH in patients with chronic HBV/HDV infection and liver cirrhosis.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 11 (estimated)
- First submitted
- 13 Apr 2021
- Start date
- 7 May 2021
- Primary completion date
- 30 Nov 2024
- Lead sponsor
- Hannover Medical School
- Diseases
- Hepatitis B, High blood pressure
- NCT number
- NCT04863703
What you commit to
- Study type: Observational
- Planned participants: 11
- From 7 May 2021 to the primary completion date, 30 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- age \<18years
Other
- patient rejects study participation
- no conducted or no indication for HVPG measurement
Who the study is looking for
- Chronic HBV/HDV Coinfection
- suspected or diagnosed liver cirrhosis, indication for hepatovenous pressure gradient (HVPG) measurement or liver cirrhosis and HVPG measurement conducted in the past 12 months (conducted prior to antiviral treatment)
- indication for antiviral treatment with Bulevirtide
- age \>18years
- Must be willing to participate in the study and provide written informed consent
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hannover Medical School Coordinator of this site? Confirm its status | Hanover | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.